1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Biotechnology
RBC Bioscience Corporation

RBC Bioscience Corporation

TTPEX:6848
20.80
TWD
-0.15
(-0.72%)
289.75MMarket Cap
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
15.13
18.58
47.22
19.31
12.18
12.08
14.38
- -
- -
Basic EPS, GAAP
- -
1.64
1.66
11.65
2.21
0.26
0.45
1.51
- -
- -
Free Cash Flow per Basic Share
- -
-7.94
3.5
7.17
-36.54
-0.24
0.47
3.2
- -
- -
Dividend per Share
- -
2.36
1.41
4.5
1.11
0.83
1.02
0.91
- -
- -
Book Value per Share
5.66
5.99
6.15
12.24
17.99
17.43
16.86
17.47
- -
18.22
Tangible Book Value per Share
5.32
5.69
5.87
11.99
17.77
17.26
16.64
16.56
- -
17.12
Basic Weighted Avg Shares
14
8
9
12
13
14
14
14
14
14
Sales/Revenue/Turnover
- -
126
162
575
251
174
172
205
- -
- -
Operating Margin (%)
- -
11.19
12.1
32.75
19.2
4.4
8.49
17.44
- -
- -
Depreciation Expense
- -
6
10
14
20
20
19
18
- -
- -
Net Income, GAAP
- -
14
14
142
29
4
6
22
- -
- -
Effective Tax Rate (%)
- -
19.88
19.81
19.99
20.08
23.15
18.33
20.01
- -
- -
Profit Margin (%)
- -
10.87
8.94
24.67
11.44
2.17
3.73
10.51
- -
- -
Working Capital
61
42
35
20
61
33
40
45
- -
10
LT Debt
- -
40
47
42
442
417
413
401
- -
340
Total Equity
81
86
88
175
257
249
241
249
- -
260
Return on Invested Capital (%)
- -
10.55
9.9
51.94
6.36
0.76
1.59
3.87
- -
- -
Return on Capital (%)
- -
12.78
9.66
49.36
5.63
1.23
1.97
4.1
- -
- -
Return on Common Equity (%)
- -
16.47
16.69
108.13
13.31
1.49
2.63
8.8
- -
- -

Capital Structure

TWD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
ST Debt
82
- -
72
LT Borrowings
378
- -
340
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
14
14
14
Market Capitalization
239
241
290

Working Capital

TWD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
Total Current Assets
150
- -
133
Cash, Cash Equivalents & STI
61
- -
43
Accounts Receivable, Net
28
- -
29
Inventories
50
- -
48
Total Current Liabilities
117
- -
123
Payables & Accruals
- -
- -
- -
ST Debt
82
- -
72
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
- -
Free Cash Flow
- -
- -
- -
Net Income, GAAP
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
205
2025
- -
- -
- -
2026
- -
- -
- -

Semi-annual Earnings Per Share

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
1.51
2025
- -
- -
- -
2026
- -
- -
- -

Semi-annual Dividends Per Share

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
0.91
2025
- -
- -
- -
2026
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Ming Wei Zhuo
Full Time Employees
50
Sector
Health technology
Industry
Biotechnology
Address
No. 15, Qiaohe Road New TaiPei TP Taiwan 235029
IPO Date
Oct 25, 2021
Website
rbcbioscience.com
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
RBC Bioscience Corporation (6848.TWO) researches, develops, manufactures, and sells reagents and automated devices for life science research and molecular diagnostics; its core offerings include molecular biomedical diagnostic and research reagents, Real Genomics branded nucleic acid extraction kits, MagCore automated nucleic acid extraction systems such as MagCore EDA for DNA/RNA extraction combined with PCR setup, gene extraction reagent kits, automated testing instruments, HIT Competent cells for rapid transformation, OnePick Blunt End Cloning Vectors, and related automation solutions like spectrophotometers, HEPA-filtered systems, and LIMS-compatible workflows. Founded in 2003 and headquartered in New Taipei City, Taiwan, the ISO 9001-, CE-, and QMS-certified company operates globally with distributors in over 27 countries, including strong presences in Europe (Italy, Spain, Germany, Netherlands), Asia, and North America, targeting clinical diagnostics, forensics, research laboratories, and molecular biology applications. Recent developments encompass sustained dividend payments including a TWD 0.30 per share semi-annual payout declared in August 2025, ongoing innovation in automated extraction technologies following the 2022 MagCore EDA launch, and recapitalization efforts since 2006 to support international molecular diagnostic market expansion.